News

The proposed Phase I study is a multi-center, open label, dose escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP in patients with advanced

The company has reported net sales of $3.13 billion for the fourth quarter of 2008, an increase of 4%, compared to $3 billion posted in the fourth quarter

Genpharm has also received final FDA approval for its abbreviated new drug application (ANDA) for a separate lamotrigine product, lamotrigine tablets chewable dispersible (CD). Mylan Pharmaceuticals’s and Genpharm’s

The company reported GAAP earnings per share from continuing operations of $0.29. On a non-GAAP basis, which includes the adjustments noted in the attached reconciliation, the company announced

PT1.2 is based on a new class of antibacterial proteins called small, acid-soluble spore proteins (SASP) which bind to bacterial DNA resulting in rapid ‘speed of kill’. Phico

According to the company, Pearl fractional is the only fractional ablative laser based on the 2,790nm wavelength with proprietary YSGG technology. Pearl fractional received FDA clearance and CE

The funds serve as a milestone payment to Omeros for having successfully met preclinical compound optimization criteria. Omeros’s schizophrenia product candidates inhibit the phosphodiesterase 10 (PDE10) enzyme. Omeros

Under the terms of the agreement, Critical Pharmaceuticals licenses an anti-obesity drug product that they have developed using their patented technology known as CriticalSorb to Global Health Ventures

SharePlan is an advanced treatment planning solution that enables transfer of treatment plans between TomoTherapy HiArt systems and conventional linear accelerators. The product uses highly sophisticated algorithms to